...
首页> 外文期刊>International Journal of Biomedical and Advance Research >Effects of pyridoxal phosphate in analysis of aminotransferase activity in patients undergoing hemodialysis
【24h】

Effects of pyridoxal phosphate in analysis of aminotransferase activity in patients undergoing hemodialysis

机译:磷酸吡ido醛对血液透析患者转氨酶活性的影响

获取原文
           

摘要

Background and Aims: Factors like hemodilution, pyridoxine deficiency, hepatocyte growth factor and uremic toxins have been proposed for low aminotransferase activity in chronic kidney disease (CKD) patients undergoing haemodialysis. This may be a concerning factor in making diagnosis of liver disorders like hepatitis in patients undergoing haemodialysis. In present study we attempted to find out the cause of hypoaminotransferasemia in chronic kidney diseases and biochemical principle of analysis. Materials and Methods: Serum levels of various biochemical parameters are measured in CKD patients undergoing haemodialysis. The serum activities of Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) are determined (with and without the addition of PLP) in a group of 176 patients undergoing hemodialysis Results: Serum AST and ALT activities are significantly lower in the CKD patients compared to the control group (P value 0.0003 and 0.001 respectively). Measurement of activity with pyridoxal phosphate containing reagent resulted into a significant increase in values comparison to without pyridoxal phosphate. The percentage activation is higher in patients as compared to controls. Conclusion: The upper limit of reference range for aminotransferases in CKD patients undergoing hemodialysis should be considered lower as compared to healthy subjects. Reagent containing pyridoxal phosphate is considered appropriate for aminotransferase activity measurement.
机译:背景与目的:血液稀释,吡ido醇缺乏,肝细胞生长因子和尿毒症毒素等因素已被提议用于接受血液透析的慢性肾脏疾病(CKD)患者的低氨基转移酶活性。这可能是诊断接受血液透析患者肝病(如肝炎)的重要因素。在本研究中,我们试图找出引起慢性肾脏疾病的低氨基转移性贫血的原因并分析其生化原理。材料和方法:在接受血液透析的CKD患者中测量各种生化指标的血清水平。在一组176名接受血液透析的患者中测定了天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)的血清活性(有或没有添加PLP)结果:与之相比,CKD患者的血清AST和ALT活性显着低于对照组(P值分别为0.0003和0.001)。与不含磷酸吡ido醛的试剂相比,使用含磷酸吡ido醛的试剂的活性测量导致值显着增加。与对照组相比,患者的激活百分比更高。结论:与健康受试者相比,接受血液透析的CKD患者的氨基转移酶参考范围的上限应被认为较低。含吡ido醛磷酸酯的试剂被认为适合氨基转移酶活性的测量。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号